Cargando…
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
HER2 gene-protein assay (GPA) is a new method for the simultaneous evaluation of HER2 immunohistochemistry (IHC) and HER2 dual in situ hybridization (DISH) on single tissue sections of breast cancer. We investigated the presence of HER2 gene and protein discrepancy and HER2-heterogeneity using HER2-...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937084/ https://www.ncbi.nlm.nih.gov/pubmed/27318853 http://dx.doi.org/10.1007/s10549-016-3856-2 |
_version_ | 1782441648569974784 |
---|---|
author | Kurozumi, Sasagu Padilla, Mary Kurosumi, Masafumi Matsumoto, Hiroshi Inoue, Kenichi Horiguchi, Jun Takeyoshi, Izumi Oyama, Tetsunari Ranger-Moore, Jim Allred, D. Craig Dennis, Eslie Nitta, Hiroaki |
author_facet | Kurozumi, Sasagu Padilla, Mary Kurosumi, Masafumi Matsumoto, Hiroshi Inoue, Kenichi Horiguchi, Jun Takeyoshi, Izumi Oyama, Tetsunari Ranger-Moore, Jim Allred, D. Craig Dennis, Eslie Nitta, Hiroaki |
author_sort | Kurozumi, Sasagu |
collection | PubMed |
description | HER2 gene-protein assay (GPA) is a new method for the simultaneous evaluation of HER2 immunohistochemistry (IHC) and HER2 dual in situ hybridization (DISH) on single tissue sections of breast cancer. We investigated the presence of HER2 gene and protein discrepancy and HER2-heterogeneity using HER2-GPA. HER2 status was analyzed for the correlation between the presence of HER2-heterogeneity and patient prognosis. Consecutive 280 invasive breast cancer were examined. Statuses of HER2 protein and gene were evaluated in whole tumor sections of HER2 GPA slides. HER2 protein and gene combination patterns were classified to six phenotypic and genotypic types for each case, as well as at individual cell levels: (A) IHC and DISH positive; (B) IHC positive and DISH negative; (C) IHC equivocal and DISH positive; (D) IHC equivocal and DISH negative; (E) IHC negative and DISH positive; and (F) IHC and DISH negative. The presence of HER2-heterogeneity was determined by the existence of at least two of six types within one tumor. HER2-IHC positive patients had significantly worse survival than IHC negative patients and HER2-DISH positive patients had significantly worse survival than DISH negative patients. HER2 IHC negative and DISH positive patients had significantly worse recurrence-free survival than IHC and DISH negative patients. In the HER2 IHC and DISH negative group, the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Notably, among triple negative breast cancer (TNBC), the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Our study suggests that the presence of HER2-heterogeneity might be a prognostic factor in HER2 negative breast cancer patients, especially in TNBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-016-3856-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4937084 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-49370842016-07-19 HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients Kurozumi, Sasagu Padilla, Mary Kurosumi, Masafumi Matsumoto, Hiroshi Inoue, Kenichi Horiguchi, Jun Takeyoshi, Izumi Oyama, Tetsunari Ranger-Moore, Jim Allred, D. Craig Dennis, Eslie Nitta, Hiroaki Breast Cancer Res Treat Clinical Trial HER2 gene-protein assay (GPA) is a new method for the simultaneous evaluation of HER2 immunohistochemistry (IHC) and HER2 dual in situ hybridization (DISH) on single tissue sections of breast cancer. We investigated the presence of HER2 gene and protein discrepancy and HER2-heterogeneity using HER2-GPA. HER2 status was analyzed for the correlation between the presence of HER2-heterogeneity and patient prognosis. Consecutive 280 invasive breast cancer were examined. Statuses of HER2 protein and gene were evaluated in whole tumor sections of HER2 GPA slides. HER2 protein and gene combination patterns were classified to six phenotypic and genotypic types for each case, as well as at individual cell levels: (A) IHC and DISH positive; (B) IHC positive and DISH negative; (C) IHC equivocal and DISH positive; (D) IHC equivocal and DISH negative; (E) IHC negative and DISH positive; and (F) IHC and DISH negative. The presence of HER2-heterogeneity was determined by the existence of at least two of six types within one tumor. HER2-IHC positive patients had significantly worse survival than IHC negative patients and HER2-DISH positive patients had significantly worse survival than DISH negative patients. HER2 IHC negative and DISH positive patients had significantly worse recurrence-free survival than IHC and DISH negative patients. In the HER2 IHC and DISH negative group, the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Notably, among triple negative breast cancer (TNBC), the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Our study suggests that the presence of HER2-heterogeneity might be a prognostic factor in HER2 negative breast cancer patients, especially in TNBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-016-3856-2) contains supplementary material, which is available to authorized users. Springer US 2016-06-18 2016 /pmc/articles/PMC4937084/ /pubmed/27318853 http://dx.doi.org/10.1007/s10549-016-3856-2 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Clinical Trial Kurozumi, Sasagu Padilla, Mary Kurosumi, Masafumi Matsumoto, Hiroshi Inoue, Kenichi Horiguchi, Jun Takeyoshi, Izumi Oyama, Tetsunari Ranger-Moore, Jim Allred, D. Craig Dennis, Eslie Nitta, Hiroaki HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients |
title | HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients |
title_full | HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients |
title_fullStr | HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients |
title_full_unstemmed | HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients |
title_short | HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients |
title_sort | her2 intratumoral heterogeneity analyses by concurrent her2 gene and protein assessment for the prognosis of her2 negative invasive breast cancer patients |
topic | Clinical Trial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937084/ https://www.ncbi.nlm.nih.gov/pubmed/27318853 http://dx.doi.org/10.1007/s10549-016-3856-2 |
work_keys_str_mv | AT kurozumisasagu her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT padillamary her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT kurosumimasafumi her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT matsumotohiroshi her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT inouekenichi her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT horiguchijun her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT takeyoshiizumi her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT oyamatetsunari her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT rangermoorejim her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT allreddcraig her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT denniseslie her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients AT nittahiroaki her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients |